HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burak, Z. Articles by Basdemir, G. Search for Related Content PubMed PubMed Citation Articles by Burak, Z. Articles by Basdemir, G.

^99mTc-MIBI Imaging as a Predictor of Therapy Response in Osteosarcoma Compared with Multidrug Resistance-Associated Protein and P-Glycoprotein Expression

Zeynep Burak, MD¹, Jean-Luc Moretti, MD, PhD², Özden Ersoy, MD³, Ulus Sanl, MD⁴, Mehmet Kantar, MD⁵, Feyzi Tamgac, MD² and Gülçin Basdemir, MD³

¹ Department of Nuclear Medicine, Ege University Medical Faculty, zmir, Turkey
² Research Unit of Tumoral Tracers, Avicenne University Hospital, Paris North University, Paris, France
³ Department of Pathology, Ege University Medical Faculty, zmir, Turkey
⁴ Department of Medical Oncology, Ege University Medical Faculty, zmir, Turkey
⁵ Department of Pediatric Oncology, Ege University Medical Faculty, zmir, Turkey

In vitro studies have demonstrated that ^99mTc-methoxyisobutylisonitrile (^99mTc-MIBI) is a transport substrate of multidrug resistance (MDR)-related proteins. The aim of this clinical study was to evaluate whether ^99mTc-MIBI scintigraphy was a functional imaging tool for in vivo detection of multidrug resistance-associated protein (MRP) expression in osteosarcoma and to investigate the role of MRP and ^99mTc-MIBI imaging to predict the clinical outcome. We also examined whether the scintigraphic parameters would help to distinguish the functional capacity of P-glycoprotein (Pgp) and MRP. Methods: Twenty-four patients with a diagnosis of osteosarcoma were studied before neoadjuvant chemotherapy. Tumor-to-background ratios of both early (10 min) and delayed (1 h) images and the percentage washout rate (WR%) of ^99mTc-MIBI were calculated. Immunohistochemical analysis of MRP and Pgp was performed on biopsy specimens, and the response to preoperative chemotherapy was assessed by histopathologic examination. Results: Fifteen of 24 osteosarcoma samples in our series (62.5%) showed significant expression of MRP. The level of MRP expression was significantly correlated with the WR% of ^99mTc-MIBI (r = 0.58, P = 0.003), and the WR% of ^99mTc-MIBI was significantly faster in patients with high MRP expression than in those with a low MRP score (P = 0.007). The clearance rate of ^99mTc-MIBI was significantly slower in tumor samples with negative or low expression of both Pgp and MRP (16% ± 6.2%) when compared with osteosarcomas with high expression of both proteins (31.7% ± 8.7%) (P = 0.001). There was not a significant difference between the WR% of ^99mTc-MIBI in tumors with coexpression of both proteins and in tumors with high expression of either Pgp or MRP. Both the rate of MRP expression and the WR% of ^99mTc-MIBI were significantly correlated with response rate. Conclusion: Our results suggest that the WR% of ^99mTc-MIBI is correlated with MRP expression. Both the WR% of ^99mTc-MIBI and MRP expression are correlated with therapy response. ^99mTc-MIBI can be used as a general probe for functional imaging of both Pgp and MRP; however, it is not capable of differentiating the functional status of either MDR-related glycoprotein.

Key Words: multidrug resistance • multidrug resistance-associated protein • P-glycoprotein • osteosarcoma • ^99mTc-methoxyisobutylisonitrile

This article has been cited by other articles:

				V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]